A guide to MyRisk testing
Determine the best treatment options for your patient

The MyRisk Hereditary Cancer multi-gene panel analyzes risk for 11 cancers of focus to determine if your patient has a germline genetic mutation associated with an increased cancer risk. Receive test results in 14 days or less.

RiskScore®

RiskScore is a clinically validated tool which uses genetic markers and clinical risk factors to predict a 5-year and remaining lifetime risk of developing breast cancer.*

For certain women who receive a positive MyRisk result in CHEK2, RiskScore can provide a comprehensive, individualized risk estimate rather than a range, informing a screening and prevention plan with an individualized precision risk assessment.*

MyRisk provides accurate germline test results in 14 days or less. These results can impact your patient’s therapy options, and the process can be easily integrated into your practice.
**Genetic testing can help guide treatment for your patient**

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>PARP Inhibitor Therapy Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast Cancer</td>
<td>PARP inhibitor therapy has been shown to cut the risk of disease progression or death by up to 46% for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation (gBRCA).¹²²</td>
</tr>
<tr>
<td>Ovarian Cancer</td>
<td>PARP inhibitor therapy has been shown to cut the risk of disease progression or death up to 70% for patients with ovarian cancer and a gBRCA mutation.³</td>
</tr>
<tr>
<td>Pancreatic Cancer</td>
<td>PARP inhibitor therapy may cut the risk of disease progression or death up to 47% for patients with pancreatic cancer and a gBRCA mutation.⁴</td>
</tr>
<tr>
<td>Prostate Cancer</td>
<td>PARP inhibitor therapy may cut the risk of disease progression or death up to 66% in patients with prostate cancer and a gBRCA mutation.⁵</td>
</tr>
</tbody>
</table>

**Tumor testing cannot replace germline testing**

- Germline and tumor BRCA testing differ in test coverage, variant classification, and detection of large rearrangements.
- In the SOLO-1 trial, 5% of known gBRCA carriers did not have their deleterious mutation identified with tumor testing.³
- NCCN Guidelines® recommend germline testing in the workup for patients diagnosed with, or after the confirmation of, ovarian, metastatic breast, and pancreatic cancer.⁵⁻⁷

---

Myriad Genetics provides the most accurate results

**Right result**

- Gradishar et al. 2017 showed that Myriad Genetics provided definitive classification for up to 63% of variants that other labs could not.

- Balmana et al. 2016 found that over 1/3 of conflicting classifications may alter patients’ medical management.

- MyRisk™ and its variant classification techniques have been independently validated.

**Lifetime commitment: MyVision® Myriad Variant Classification Program**

Myriad Genetics has a lifetime commitment to patients with its variant classification program, with over 60,000 amended reports with updated classifications sent out between 2006-2016.

- 9% of amended reports impacted recommended medical management for patients.
Tools to make the testing process easy for you

Myriad provides easy-to-use resources that can seamlessly integrate genetic testing into your practice

**Patient identification**  
based on medical society guidelines  
- Digital screening with MyGeneHistory™  
- Radiology Information Systems  
- Mammography Information Systems

**Pre-test education***  
with a Certified Genetic Counselor  
- Individualized education (on-demand)  
- Follow-up documentation:  
  - Pre-populated test request form  
  - Three-generation pedigree  
  - Chart note

*must be enrolled in Patient Education program

**Affordability**  
- Personalized cost estimates  
- 9 out of 10 pay $0  
- Financial assistance and payment plans for those that qualify

**Ordering**  
- Online portal  
- Virtual orders  
- EMR integrations  
- Phlebotomy support

**Results**  
with MyRisk™ Management Tool  
- Personalized Tyrer-Cuzick/RiskScore® when applicable

**Post-test consults**  
with a Certified Genetic Counselor  
- Individualized discussion of results (on-demand or scheduled)  
- Detailed summary notes
Myriad Genetics’ commitment to you

Cost should never be a barrier when your patients need genetic testing to determine their next treatment. That’s why it’s our promise to make it accessible and affordable. Through insurance and financial assistance:

**Satisfaction**

95%

Insurers have coverage for hereditary cancer testing

**Affordable**

75%

Patients pay $0 for testing at Myriad Genetics

≥90%

Patients have or will qualify for a payment of $100 or less

**Accessible**

100%

Patients covered by the Myriad Promise

---

**Genetic testing that’s affordable, results that are secure**

**Assistance**

Myriad Genetics’ Financial Assistance Program (MFAP) can help if your patients have a high deductible or co-insurance. With MFAP, they may qualify for $0 or reduced out-of-pocket cost, dependent on family size and income.†

**Privacy**

Myriad Genetics will not release your patient’s data to public databases without their knowledge. As a co-founder of PROMPT, we believe patients should control what they do with their data. For information about Myriad Genetics’ privacy policy, visit www.myriad.com/patients-families/the-myriad-difference/your-privacy.

**Protection**

The Genetic Information Non-discrimination Act (GINA) and laws in most states prohibit discrimination regarding employment eligibility, health benefits, or health insurance premiums solely on the basis of genetic information.

---

844-697-4239 / billinghelp@myriad.com / www.MyriadPro.com

The Genetic Information Non-discrimination Act (GINA) and laws in most states prohibit discrimination regarding employment eligibility, health benefits, or health insurance premiums solely on the basis of genetic information. For information about Myriad Genetics’ privacy policy, visit www.myriad.com/patients-families/the-myriad-difference/your-privacy.

† Patients who are recipients of U.S. government-funded programs such as Medicaid, Medicare, Medicare-Advantage and Tricare may not be eligible.
### Red flags for hereditary cancer

#### Personal history of:
- Breast cancer at any age
- Ovarian cancer at any age
- Metastatic prostate cancer at any age
- Pancreatic cancer at any age
- Colon or rectal cancer at any age
- Uterine/endometrial cancer at age 64 or younger

#### Family history of:
- Breast cancer at age 49 or younger
- Two breast cancers in one relative at any age
- Three or more breast cancers in relatives on the same side of the family at any age
- Ovarian, metastatic prostate, pancreatic, or male breast cancer at any age
- Colon, rectal, uterine cancer at age 49 or younger (1st degree relative)
- A gene mutation found in a family member
- Ashkenazi Jewish ancestry with breast cancer at any age